| Year |
Citation |
Score |
| 2020 |
Truong AS, Zhou M, Utsumi T, Krishnan B, Stewart KG, Saito R, Manocha U, Bailey ST, Kim WY. Abstract A13: Entinostat enhances antitumor immune responses and cooperates with PD-1 blockade in bladder cancer mouse models Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Bladder19-A13 |
0.427 |
|
| 2018 |
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, ... ... Krishnan B, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23: 3698. PMID 29925010 DOI: 10.1016/J.Celrep.2018.06.032 |
0.307 |
|
| 2018 |
Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Haake S, ... ... Krishnan B, et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports. 23: 313-326.e5. PMID 29617669 DOI: 10.1016/J.Celrep.2018.03.075 |
0.359 |
|
| 2018 |
Kardos J, Bixby L, Truong A, Krishnan B, Stewart K, Vincent B, Kim W. Abstract 2749: Effects of subtype specific chemotherapeutic immunomodulation in bladder cancer Cancer Research. 78: 2749-2749. DOI: 10.1158/1538-7445.Am2018-2749 |
0.404 |
|
| 2018 |
Stewart KG, Truong AS, Krishnan B, Zhou M, Saito R, Kardos J, Manocha U, Bailey ST, Kim WY. Abstract 2748: Antitumor activity of HDAC inhibition in bladder cancer mouse models correlates with enhanced immune response Immunology. DOI: 10.1158/1538-7445.Am2018-2748 |
0.409 |
|
| 2017 |
Bailey ST, Smith AM, Kardos J, Wobker SE, Wilson HL, Krishnan B, Saito R, Lee HJ, Zhang J, Eaton SC, Williams LA, Manocha U, Peters DJ, Pan X, Carroll TJ, et al. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nature Communications. 8: 15770. PMID 28593993 DOI: 10.1038/Ncomms15770 |
0.386 |
|
| 2017 |
Smith CC, Saito R, Bixby LM, Utsumi T, Kardos J, Chai S, Wobker SE, Krishnan B, Damrauer JS, Serody JS, Darr D, Vincent BG, Kim WY. Abstract 1654: Development of subtype specific mouse models of bladder cancer Cancer Research. 77: 1654-1654. DOI: 10.1158/1538-7445.Am2017-1654 |
0.476 |
|
| 2017 |
Saito R, Smith C, Kardos J, Bixby L, Chai S, Damrauer J, Utsumi T, Wobker S, Krishnan B, Ogawa O, Vincent B, Kim W. Mp88-20 Establishment Of Novel Mouse Bladder Cancer Cell Lines Mimicking Intrinsic Subtype Of Human Invasive Bladder Cancer The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2745 |
0.461 |
|
| 2016 |
Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, Iglesia MD, Milowsky MI, Parker JS, Kim WY, Vincent BG. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. Jci Insight. 1: e85902. PMID 27699256 DOI: 10.1172/Jci.Insight.85902 |
0.36 |
|
| 2016 |
Krishnan B, Rose TL, Kardos J, Milowsky MI, Kim WY. Intrinsic Genomic Differences Between African American and White Patients With Clear Cell Renal Cell Carcinoma. Jama Oncology. PMID 27010573 DOI: 10.1001/Jamaoncol.2016.0005 |
0.304 |
|
| 2016 |
Rose TL, Krishnan B, Kuykendal AR, Smith A, Milowsky MI, Kim WY. Genomic differences and survival in African Americans with metastatic clear cell renal cell carcinoma in the targeted therapy era. Journal of Clinical Oncology. 34: 504-504. DOI: 10.1200/Jco.2016.34.2_Suppl.504 |
0.356 |
|
| 2015 |
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, ... ... Krishnan B, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 26536169 DOI: 10.1056/Nejmoa1505917 |
0.314 |
|
| 2014 |
Bailey ST, Zhou B, Damrauer JS, Krishnan B, Wilson HL, Smith AM, Li M, Yeh JJ, Kim WY. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma. Plos One. 9: e104413. PMID 25180793 DOI: 10.1371/Journal.Pone.0104413 |
0.339 |
|
| 2014 |
Krishnan B, Hanna S, Wilson H, Bailey S, Damrauer J, Simamura T, Levine R, Wong K, Johnson G, Kim W. 299 Tyk2-src dependence of kidney cancer European Journal of Cancer. 50: 98. DOI: 10.1016/S0959-8049(14)70425-3 |
0.325 |
|
| 2013 |
Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET, Superfine R, Miller CR, Simon MC, Wong KK, Kim WY. HIF1α and HIF2α independently activate SRC to promote melanoma metastases. The Journal of Clinical Investigation. 123: 2078-93. PMID 23563312 DOI: 10.1172/Jci66715 |
0.358 |
|
| 2013 |
Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. The Prostate. 73: 71-82. PMID 22644942 DOI: 10.1002/Pros.22542 |
0.63 |
|
| 2013 |
Krishnan B, Torti FM, Gallagher PE, Tallant EA. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. The Prostate. 73: 60-70. PMID 22644934 DOI: 10.1002/Pros.22540 |
0.643 |
|
| 2011 |
Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Tallant EA, Gallagher PE. Abstract 550: Angiotensin-(1-7) inhibits prostate cancer angiogenesis and metastasis to bone Cancer Research. 71: 550-550. DOI: 10.1158/1538-7445.Am2011-550 |
0.658 |
|
| 2011 |
Gallagher PE, Maglic D, Krishnan B, Castellino SM, Tallant EA. Abstract 5349: Angiotensin-(1-7) inhibits the growth of human pediatric rhabdomyosarcoma in a mouse xenograft model Cancer Research. 71: 5349-5349. DOI: 10.1158/1538-7445.Am2011-5349 |
0.546 |
|
| 2010 |
Krishnan B, Gallagher PE, Tallant EA. Abstract 1299: Angiotensin-(1-7) inhibits angiogenesis in human prostate cancer xenografts through an increase in soluble vascular endothelial growth factor receptor 1 (sFLT1) Cancer Research. 70: 1299-1299. DOI: 10.1158/1538-7445.Am10-1299 |
0.632 |
|
| Show low-probability matches. |